| Literature DB >> 32530623 |
Fleur M Ferguson1, Yan Liu2, Wayne Harshbarger2, Ling Huang3, Jinhua Wang1, Xianming Deng1, Stephen J Capuzzi4, Eugene N Muratov4, Alexander Tropsha4, Senthil Muthuswamy3,5, Kenneth D Westover2, Nathanael S Gray1.
Abstract
Doublecortin-like kinase 1 (DCLK1) is a serine/threonine kinase that is overexpressed in gastrointestinal cancers, including esophageal, gastric, colorectal, and pancreatic cancers. DCLK1 is also used as a marker of tuft cells, which regulate type II immunity in the gut. However, the substrates and functions of DCLK1 are understudied. We recently described the first selective DCLK1/2 inhibitor, DCLK1-IN-1, developed to aid the functional characterization of this important kinase. Here we describe the synthesis and structure-activity relationships of 5,11-dihydro-6H-benzo[e]pyrimido[5,4-b][1,4]diazepin-6-one DCLK1 inhibitors, resulting in the identification of DCLK1-IN-1.Entities:
Mesh:
Substances:
Year: 2020 PMID: 32530623 DOI: 10.1021/acs.jmedchem.0c00596
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446